MiMedx Group (MDXG) Aperçu de l'action
MiMedx Group, Inc. développe et distribue des allogreffes de tissu placentaire pour divers secteurs de la santé. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 2/6 |
| Croissance future | 3/6 |
| Performances passées | 2/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
MDXG Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
MiMedx Group, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$4.27 |
| Plus haut sur 52 semaines | US$7.97 |
| Plus bas sur 52 semaines | US$3.03 |
| Bêta | 1.41 |
| Variation sur 1 mois | 8.10% |
| Variation sur 3 mois | 16.67% |
| Variation sur 1 an | -38.74% |
| Variation sur 3 ans | -41.75% |
| Variation sur 5 ans | -64.21% |
| Évolution depuis l'introduction en bourse | -16.27% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jul 02
MDXG: Index Shifts And Guidance Reset Will Present Undervalued Entry Opportunity
MiMedx Group's analyst price targets have been reduced by a combined few dollars across several firms, with the new consensus anchoring to a lower fair value near $5.00 as analysts factor in softer revenue growth expectations, slightly higher profit margins, and updated P/E assumptions. Analyst Commentary Recent Street research on MiMedx Group centers on a series of price target cuts that cluster around the new consensus near US$5.00.
Mise à jour du récit • Jun 18
MDXG: New Wound Care Launches Will Support Chronic Biologics Comeback Narrative
MiMedx Group's consensus analyst price target has been reduced by several dollars to reflect updated assumptions on discount rates, revenue growth, profit margins, and future P/E, with analysts citing recent target cuts from several firms as they refine their outlook on the stock. Analyst Commentary Recent research updates on MiMedx Group point to a more cautious stance on valuation, with several firms trimming price targets by varying dollar amounts.Recent updates
Mise à jour du récit • Jul 02
MDXG: Index Shifts And Guidance Reset Will Present Undervalued Entry Opportunity
MiMedx Group's analyst price targets have been reduced by a combined few dollars across several firms, with the new consensus anchoring to a lower fair value near $5.00 as analysts factor in softer revenue growth expectations, slightly higher profit margins, and updated P/E assumptions. Analyst Commentary Recent Street research on MiMedx Group centers on a series of price target cuts that cluster around the new consensus near US$5.00.Mise à jour du récit • Jun 18
MDXG: New Wound Care Launches Will Support Chronic Biologics Comeback Narrative
MiMedx Group's consensus analyst price target has been reduced by several dollars to reflect updated assumptions on discount rates, revenue growth, profit margins, and future P/E, with analysts citing recent target cuts from several firms as they refine their outlook on the stock. Analyst Commentary Recent research updates on MiMedx Group point to a more cautious stance on valuation, with several firms trimming price targets by varying dollar amounts.Mise à jour du récit • Jun 04
MDXG: Future Earnings Power Will Support Chronic Wound Biologics Comeback Narrative
Analysts have trimmed their average price target on MiMedx Group by a few dollars, citing updated views on profitability and expectations for a higher future P/E multiple as key reasons for the reset. Analyst Commentary Recent Street research has focused on resetting price targets for MiMedx Group by a few dollars at a time, as analysts revisit their assumptions around profitability, execution, and what P/E multiple they are comfortable assigning to the stock.Seeking Alpha • May 09
MiMedx: The Hard Math Behind My Downgrade To Hold
Summary MiMedx Group faces a sharp downgrade from Buy to Hold as 2026 revenue guidance drops to $260–$290 million from $340–$360 million. Q1 2026 saw a 33% revenue decline, with wound care sales down 60% and surgical portfolio growth at 13%, reflecting permanent reimbursement headwinds. My DCF model, updated for lower revenue and margin assumptions, now values MDXG at $3.93 per share—just 6% above the current price, making upside limited. Management targets breakeven in Q3 via $40 million cost cuts, but execution risk remains high amid industry 'fire sale' conditions and uncertain wound care recovery. Read the full article on Seeking AlphaMise à jour du récit • May 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Comeback Narrative
Analysts have trimmed their average price targets on MiMedx Group by several dollars to reflect lower fair value estimates, softer revenue and margin assumptions, and a higher implied future P/E, as highlighted in recent research updates from multiple firms. Analyst Commentary Recent research on MiMedx Group highlights a mixed set of views, with several firms lowering price targets while still pointing to specific factors that could support value over time.
Nouveau récit • May 03
Surgical Adoption And Cost Cuts Will Reshape Long Term Potential For This Biologics Supplier
Catalysts About MiMedx Group MiMedx Group develops and markets placental tissue and related biologic products for wound care and surgical applications. What are the underlying business or industry changes driving this perspective?Mise à jour du récit • Apr 20
MDXG: Medicare Policy Reset Will Support Chronic Wound Biologics Recovery Narrative
Analysts have trimmed the average price target for MiMedx Group from about $9.67 to $8.20, citing updated assumptions for revenue growth, profit margins, and a higher future P/E following a series of recent target cuts across the Street. Analyst Commentary Recent Street research on MiMedx Group centers on how Medicare reimbursement decisions and updated modeling are feeding into price targets, ratings, and expectations for future execution.Nouveau récit • Apr 18
Reimbursement And Competition Will Pressure Margins Yet Long Term Surgical Demand Will Support Upside
Catalysts About MiMedx Group MiMedx Group develops and commercializes human placental tissue and complementary products for Wound Care and Surgical applications. What are the underlying business or industry changes driving this perspective?Mise à jour du récit • Apr 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Recovery Narrative
The consolidated analyst price target for MiMedx Group now reflects a modest adjustment of cents per share, as analysts weigh ongoing Medicare reimbursement changes and recent coverage initiations that highlight both prior headwinds and the potential for a rebound in chronic wound biologics. Analyst Commentary Recent research updates show a mix of optimism and caution around MiMedx Group, with views largely shaped by Medicare reimbursement shifts and how these might influence the value investors place on the chronic wound biologics portfolio.Mise à jour du récit • Mar 22
MDXG: CMS Reimbursement Reset Will Set Up Biologics Comeback Narrative
Analysts have adjusted their MiMedx Group price targets, with recent moves ranging from $8 to $10 per share as they factor in shifting Medicare reimbursement developments and a potential recovery from prior headwinds. Analyst Commentary Recent research on MiMedx Group reflects a mix of optimism about potential recovery and caution around reimbursement and execution risk, which feeds directly into the range of price targets between $8 and $10 per share.Mise à jour du récit • Mar 07
MDXG: Wound Care Expansion And CMS Reset Will Support Future Rebound
The analyst price target for MiMedx Group has shifted modestly to about $9.67 per share, as analysts factor in recent reimbursement headwinds that weighed on the stock, while still noting potential upside with fresh targets such as $10 from new coverage and $8 from revised models. Analyst Commentary Recent research updates around MiMedx highlight a mix of optimism about the core wound care franchise and caution around reimbursement uncertainty and valuation reset.Mise à jour du récit • Feb 21
MDXG: Wound Care Portfolio Expansion Will Offset CMS Reimbursement Uncertainty
Analysts have trimmed their price targets on MiMedx Group, with one key target moving from $12 to $8, as they revisit growth, margin and P/E assumptions following recent CMS related reimbursement updates. Analyst Commentary Recent research updates point to a reset in expectations for MiMedx Group, as analysts update their models following the CMS reimbursement developments and pull back their price targets.Mise à jour du récit • Feb 06
MDXG: Wound Care Portfolio Expansion Will Drive Future Upside Potential
Analysts have reduced their price target on MiMedx Group to about US$10.40 from roughly US$11.00. This change reflects slightly more cautious assumptions on fair value, revenue growth, profit margins, and future P/E multiples following recent research updates.Mise à jour du récit • Jan 22
MDXG: Execution On Wound Care Expansion Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for MiMedx Group from US$12.20 to US$11.00, citing updated assumptions around discount rates, revenue growth, margins, and future P/E multiples as the key drivers behind the change. Analyst Commentary Recent Street research includes lower price targets from different firms that both bring MiMedx Group’s fair value range closer to the updated estimate.Article d’analyse • Jan 09
Investors Interested In MiMedx Group, Inc.'s (NASDAQ:MDXG) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...Article d’analyse • Nov 06
MiMedx Group's (NASDAQ:MDXG) Soft Earnings Don't Show The Whole Picture
MiMedx Group, Inc.'s ( NASDAQ:MDXG ) stock was strong despite it releasing a soft earnings report last week. We think...Article d’analyse • Jul 04
MiMedx Group (NASDAQ:MDXG) Could Easily Take On More Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • Apr 17
Some Shareholders Feeling Restless Over MiMedx Group, Inc.'s (NASDAQ:MDXG) P/E Ratio
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Article d’analyse • Mar 27
MiMedx Group (NASDAQ:MDXG) Seems To Use Debt Rather Sparingly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Article d’analyse • Mar 05
Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings
The market was pleased with the recent earnings report from MiMedx Group, Inc. ( NASDAQ:MDXG ), despite the profit...Article d’analyse • Feb 22
Here's Why MiMedx Group (NASDAQ:MDXG) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Article d’analyse • Dec 23
We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Nov 21
We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Article d’analyse • Nov 06
There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise
MiMedx Group, Inc. ( NASDAQ:MDXG ) shares have had a really impressive month, gaining 27% after a shaky period...Rendement pour les actionnaires
| MDXG | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | -2.1% | 0.6% | 4.9% |
| 1Y | -38.7% | 35.2% | 21.3% |
Rendement vs Industrie: MDXG a sous-performé le secteur US Biotechs qui a rapporté 35.2 % au cours de l'année écoulée.
Rendement vs marché: MDXG a sous-performé le marché US qui a rapporté 21.3 % au cours de l'année écoulée.
Volatilité des prix
| MDXG volatility | |
|---|---|
| MDXG Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: MDXG n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de MDXG ( 5% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2006 | 808 | Joe Capper | www.mimedx.com |
MiMedx Group, Inc. développe et distribue des allogreffes de tissus placentaires pour divers secteurs de la santé. La société traite les tissus placentaires humains (membrane, cordon ombilical et disque placentaire) en utilisant son procédé breveté et exclusif PURION pour produire des allogreffes qui conservent les propriétés biologiques inhérentes au tissu et les protéines régulatrices, y compris les cytokines, les chimiokines et les facteurs de croissance. Sa méthode de traitement brevetée et exclusive utilise des techniques de traitement aseptiques en plus de la stérilisation terminale.
MiMedx Group, Inc. Résumé des fondamentaux
| MDXG statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$622.40m |
| Bénéfices(TTM) | US$6.24m |
| Recettes(TTM) | US$355.17m |
99.8x
Ratio P/E1.8x
Ratio P/SLe site MDXG est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| MDXG compte de résultat (TTM) | |
|---|---|
| Recettes | US$355.17m |
| Coût des recettes | US$75.12m |
| Marge brute | US$280.05m |
| Autres dépenses | US$273.81m |
| Les revenus | US$6.24m |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 0.043 |
| Marge brute | 78.85% |
| Marge bénéficiaire nette | 1.76% |
| Ratio dettes/capitaux propres | 8.0% |
Quelles ont été les performances à long terme de MDXG?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/04 04:06 |
| Cours de l'action en fin de journée | 2026/08/04 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
MiMedx Group, Inc. est couverte par 10 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| Sarah James | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |